NuView Life Sciences

Executive Summary

NuView Life Sciences is a clinical-stage radiopharmaceutical company developing NV-VPAC1, a proprietary small molecule targeting the VPAC1 receptor overexpressed on cancer cells. Its platform enables paired diagnostic and therapeutic applications using copper-64 and copper-67 isotopes. The company is based in Salt Lake City, Utah, and is privately held. Its lead program is in Phase 1 clinical development for cancer diagnosis and therapy. The theranostic approach aims to improve precision oncology by combining imaging and treatment with the same molecular target. Given the early-stage nature, key risks include clinical validation, manufacturing scalability, and funding. However, the VPAC1 target is novel and potentially applicable to multiple cancers, offering a differentiated value proposition in the radiopharmaceutical space. The company's progress in advancing NV-VPAC1 through clinical trials will be critical for near-term value inflection.

Upcoming Catalysts (preview)

• Q1 2027Phase 1 Clinical Data Readout for NV-VPAC1 Diagnostic Imaging30% success
• Q3 2026FDA IND Clearance for Therapeutic Arm (Cu-67)25% success
• Q4 2026Strategic Partnership or Funding Round20% success